News MMJ Files US Patent for Multiple Sclerosis Cannabinoid Treatment MMJ Files US Patent for Multiple Sclerosis Cannabinoid Treatment by Patricia Silva, PhD | November 29, 2017 Share this article: Share article via email Copy article link MMJ International Holdings has applied to the U.S. Patent and Trademark Office (USPTO) for new pharmaceutical compounds and methods to treat and prevent symptoms associated with multiple sclerosis (MS) and other diseases responsive to cannabinoids. The patent covers MMJ BioScienceās intellectual property portfolio, which comprises several patent families with issued or pending claims regarding plants, plant extracts, plant variety rights, pharmaceutical formulations, patient monitoring technology and drug delivery methods. MMJ BioScience is an affiliate of MMJ International Holdings, which is based in Reston, Virginia. The filing of these patents protects the delivery of a particular product formulation to be tested in a Phase 2 clinical trial for MS. Bianca Weinstock-Guttman, executive director of the New York State Multiple Sclerosis Consortium, will lead this Phase 2 study with the guidance ofĀ Parexel, a clinical research organization. Weinstock-Guttman is a neurology professor at theĀ State University of New York at Buffalo. MMJĀ hired her Nov. 8Ā as principal investigator of MMJ’s clinical trialsĀ exploring potential therapeutic applications of cannabinoids in progressive MS patients. The trial, which has won U.S. Food and Drug Administration (FDA) approval, will beĀ MMJās first study of cannabis-based medicines involving MS and related forms of pain and spasticity. As such, several hundred patients will receive proprietary formulations of cannabis-based medicine via an oral gel cap over 18 to 24 months. The trial will take place in New York and should begin by early 2018. “Our initiation of the Phase 2 clinical trial programs and the eventual FDA Fast Track Designation for progressive multiple sclerosis signify important steps forward in MMJ BioScience’s ongoing commitment to investigating innovative scientific approaches with the hope of bringing new treatment options to patients,” Timothy Moynahan, chairman of MMJ BioScience, said in a press release. āWe believe that this matrix of intellectual property provides MMJ Bioscience with a unique market position to benefit from the rich opportunities within the field of cannabinoid therapeutics,” Moynahan added. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags cannabinoids, cannabis, clinical trials, MMJ, patent
April 26, 2024 News by Margarida Maia, PhD Employment, income drop steadily over 2 decades after onset of MS
April 26, 2024 News by Marisa Wexler, MS Machine learning model predicts CIS to MS conversion risk: Study
April 25, 2024 Columns by Benjamin Hofmeister Finding safety while living with the constant threat of MS progression